tirzepatide pulled Compounded vs. Zepbound – Forbes Health How to Inject Tirzepatide: Easy

Cardiovascular outcomes trials (SUSTAIN-6, SELECT) demonstrate that long-term use reduces heart attack and stroke risk in people with obesity and existing heart disease

Tirzepatide (Mounjaro, Zepbound) is an FDA-approved dual GIP/GLP-1 receptor agonist for type 2 diabetes and chronic weight management, while multiple sclerosis is a chronic autoimmune disorder affecting the central nervous system

Within the first weeks to months of treatment, you may start noticing that any food noise is quieting down, you have fewer cravings, and you get full sooner during a meal and longer afterwards

Doses above 1,000 mg/day have a weaker safety profile and a higher probability of GI overlap with tirzepatide